Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rHAO Trivalent Influenza Vaccine
- Development stage
- Phase 2
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rHAO Trivalent Influenza Vaccine is a seasonal influenza vaccine that contains three viral components to protect against influenza viruses. Trivalent influenza vaccines include two influenza A viruses (H1N1 and H3N2) and one influenza B virus (B/Victoria lineage). This vaccine is part of the transition from quadrivalent (four-component) to trivalent (three-component) influenza vaccines that began with the 2024-2025 flu season, following the FDA's recommendation to remove the B/Yamagata lineage component as it has not been detected in global surveillance since March 2020.
02
Targets
NeuraminidaseHA head (Hemagglutinin globular head domain)HA head-stem interface (Influenza hemagglutinin head-stem interface epitope)
Beyond the preview
Go deeper on rHAO Trivalent Influenza Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rHAO Trivalent Influenza Vaccine.